Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice

BMC Ophthalmology

Research Article

Corinne Delahaye-Mazza¹  Gabriel Quentel¹  Salomon Y. Cohen²  Audrey Giocanti-Auregan³  Typhaine Grenet⁴  Franck Fajnkuchen⁴  Sylvia Nghiem-Buffet⁴  Ramin Tadayoni⁵ 

[1] Centre Ophtalmologique d’Imagerie et de Laser, 11 rue Antoine Bourdelle, 75015, Paris, France;Centre Ophtalmologique d’Imagerie et de Laser, 11 rue Antoine Bourdelle, 75015, Paris, France;Hôpital Intercommunal and University Paris-Est-Creteil, Creteil, France;Department of Ophthalmology, Hôpital Avicenne, AP-HP and University Paris 13-Bobigny, Seine Saint Denis, France;Departement Hospitalo-Universitaire Vision et Handicaps, Paris, France;Department of Ophthalmology, Hôpital Avicenne, AP-HP and University Paris 13-Bobigny, Seine Saint Denis, France;Departement Hospitalo-Universitaire Vision et Handicaps, Paris, France;Centre Ophtalmologique d’Imagerie et de Laser, 11 rue Antoine Bourdelle, 75015, Paris, France;Department of Ophthalmology, Hôpital Lariboisière, AP-HP and University Paris 7, Paris, France;Departement Hospitalo-Universitaire Vision et Handicaps, Paris, France;

关键词: Intravitreal injection;    Age-related macular degeneration;    Anti-VEGF;    Diabetic macular edema;    Retinal diseases;   

DOI  :  10.1186/s12886-016-0317-y

 received in 2016-04-07, accepted in 2016-08-01,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundTo estimate the need for bilateral intravitreal anti-VEGF injections in patients treated for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal neovascularization (CNV) in high myopia, and other causes of CNV.MethodsAll consecutive patients treated with intravitreal anti-VEGF injection over a 1-month period were included in a prospective multicenter survey. The reason for intravitreal anti-VEGF injection and the involvement of the fellow eye in the pathology requiring a treatment with intravitreal anti-VEGF were recorded. A time interval between bilateral injections longer than 1 month, within a 1-month period, and same-day bilateral injections were recorded.ResultsA total of 1335 patients were included, corresponding to 1024 (76.7 %) patients treated for nAMD, 167 (12.5 %) for DME, and 144 (10.8 %) for other reasons. Four hundred and fifty-nine (34.4 %) patients were treated bilaterally with a time interval between injections longer than 1 month, 170 (12.7 %) were treated bilaterally within a 1-month interval, and 87 (6.6 %) had same-day bilateral injections. Bilateral injections were more frequent in diabetic patients than in nAMD patients (respectively 48 % vs. 36 %, p = 0.0033).ConclusionsPatients with DME are more likely to be treated bilaterally with anti-VEGF injections. As the rate of second eye involvement requiring treatment increases progressively over time, a same-day bilateral injection strategy will become more common as it decreases the administrative burden on the healthcare system and treatment burden experienced by patients.

【 授权许可】

CC BY   
© The Author(s). 2016